Small Cell Lung Cancer

Ariel Lopez-Chavez, MD, discusses available frontline options for patients with small cell lung cancer, then moves into second-line treatments.

During a Community Case Forum event in partnership with the South Carolina Oncology Society, Kathryn Mileham, MD, discussed the significance of the IMpower133 and CASPIAN trials for patients with extensive-stage small cell lung cancer.

In an interview with Targeted Oncology, Penn Medicine’s Qian Wang, MD, MPH, gives an in-depth overview of the molecular targets in the small cell lung cancer field.

THIO has received 2 prior orphan drug designations, and the agent has shown promise in preclinical studies for the treatment of glioblastoma.

In an interview with Targeted Oncology, Federico Albrecht, MD, discussed advances to treatments for patients with small cell lung cancer and considerations when treating difficult cases.

Treatment with sacituzumab govitecan-hziy in the second line demonstrated responses in patients with extensive-stage small cell lung cancer, according to results from the phase 2 TROPiCS-03 trial.

Tarlatamab 10 mg showed responses in patients with previously treated small cell lung cancer, and no new safety signals were observed.

Qian Wang, MD, MPH, discusses the progress of research into the molecular pathways responsible for developing small cell lung cancer.

BI 764532 is under investigation in a first-in-human phase 1 trial for patients with extensive-stage small cell lung cancer and extrapulmonary neuroendocrine carcinoma.

Following positive phase 1 results, HPN328 treatment in now under evaluation in a phase 1/2 trial.

A phase 2 study, PUMA-ALI-4201, will further investigate alisertib for the treatment of small cell lung cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Jason Porter, MD, discussed with participants how they would treat a patient with small cell lung cancer after prior treatment with carboplatin plus etoposide.

The push for more screening of patients with a history of smoking is providing oncologists the ability to catch small cell lung cancers earlier and potentially change the prognosis of the disease.

Trilaciclib was found to to be a promising new treatment for chemotherapy-induced myelosuppression prevention and other benefits for patients with extensive-stage small cell lung cancer.

Responses to BI 764532 in patient siwth DLL3-positive small cell lung cancer appear to be durable and are ongoing in the dose optimization portion of a phase 1 study.

Investigators reported the best objective response, progression-free survival, overall survival, and safety of a B7-H3–directed antibody-drug conjugate at the 2023 World Conference on Lung Cancer.

Phase 3 ETER701 study results reveal the benefit of adding benmelstobart to the standard combination of anlotinib and chemotherapy.

The DeLLphi-300 trial of a bispecific T-cell engager showed favorable outcomes in patients with previously treated small cell lung cancer.

Federico Albrecht, MD, comments on clinical trials supporting the use of PD-L1 inhibitor therapy in combination with standard chemotherapy for the treatment of patients with extensive-stage small cell lung cancer.

A phase 1/2 study marks the beginning of Genprex, Inc's clinical development of quratusugene ozeplasmid in small cell lung cancer.

Sagun Shrestha, MD, discusses new trials that are exploring anti PD-1 therapy in the first-line setting for patients with small cell lung cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Ticiana Leal, MD, discussed treatment options for recurrent extensive-stage small cell lung cancer, including topotecan, lurbinectedin, and platinum rechallenge.

In an interview with Targeted Oncology, Sagun Shrestha, MD, evaluated new developments and clinical trials for patients with extensive-stage small cell lung cancer.

Sagun Shrestha, MD, discusses how the addition of atezolizumab and durvalumab to treatment options for patients with extensive stage small cell lung cancer has impacted the field for the better.

A fast track designation has been granted by the FDA to quaratusugene ozeplasmid with atezolizumab for the treatment patients with extensive-stage small cell lung cancer.

The investigational agent, ABBV-011, is showing promise, according to results from a phase 1 clinical trial.

Further dose optimization is ongoing in the phase 1 study of BI 764532 following the read-out of positive results.

Lurbinectedin yielded a value of 6.52 nM on the key pharmacological efficacy variable IC50, according to a poster presented at the 2023 Annual Meeting of the American Association for Cancer Research

Qian Wang, MD, MPH, looks at the important metrics related to a patient’s smoking history that helps to determine their level of risk for developing small cell lung cancer.